A Randomized, 26-week, Open-label, 2-treatment Arm, Parallel Group Multicenter Study Comparing the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed-ratio Combination (Soliqua) Titrated Using a Simple Titration Algorithm (One Unit Daily Adjustment) Compared With Insulin Glargine/Lixisenatide Fixed-ratio Combination (Soliqua) Titrated by Weekly Adjustment in Patients With Type 2 Diabetes Mellitus (T2DM)
Phase of Trial: Phase III
Latest Information Update: 25 Mar 2019
Price : $35 *
At a glance
- Drugs Insulin-glargine/lixisenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms LixilanOne CAN
- Sponsors Sanofi
- 01 Mar 2019 Planned End Date changed from 1 Apr 2020 to 1 Jun 2020.
- 01 Mar 2019 Planned primary completion date changed from 1 Apr 2020 to 1 Jun 2020.
- 01 Mar 2019 Status changed from not yet recruiting to recruiting.